Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | CAMK1D | Q8IU85 | 3/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382986 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAHTTHRH3CAMK1D | |
| SCHEMBL5383937 | 0.78 | HTR2C (0.35) | ALDH1A1LMNAHPGDHRH3CAMK1D | |
| SCHEMBL5391106 | 0.78 | NPSR1 (0.38) | ALDH1A1LMNAHTTHRH3HRH4 | |
| SCHEMBL5380895 | 0.76 | TSHR (0.34) | ALDH1A1LMNAHRH3HRH4CAMK1D | |
| SCHEMBL5380621 | 0.75 | ADRA1D (0.31) | — | |
| SCHEMBL5378356 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HTTHPGDNPSR1 | |
| SCHEMBL5383240 | 0.74 | HRH3 (0.42) | HRH3HRH4 | |
| SCHEMBL5388227 | 0.72 | ALDH1A1 (0.40) | ALDH1A1HTTCAMK1D | |
| SCHEMBL5385029 | 0.72 | HRH4 (0.40) | HRH3HRH4CAMK1D | |
| SCHEMBL5381097 | 0.72 | PTPN11 (0.33) | HRH3CAMK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | ANADYS PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | ALDH1A1 2233/4885LMNA 4065/4885HTT 949/4885 |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | AMPD3, AAAS, PEPD | ALDH1A1 2096/4885LMNA 4008/4885HTT 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.